STOCK TITAN
  1. Home
  2. News
  3. UCBJY

UCB SA - UCBJY STOCK NEWS

IMPACT
SENTIMENT
UCBJY : OTC
The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care
conferences
IMPACT
SENTIMENT
UCBJY : OTC
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)
IMPACT
SENTIMENT
UCBJY : OTC
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
IMPACT
SENTIMENT
UCBJY : OTC
Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022
IMPACT
SENTIMENT
UCBJY : OTC
UCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS
IMPACT
SENTIMENT
UCBJY : OTC
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
IMPACT
SENTIMENT
UCBJY : OTC
New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis
IMPACT
SENTIMENT
UCBJY : OTC
UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress
Stock UCBJY logo
UCB SA

OTC:UCBJY

UCBJY Rankings

#794 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

UCBJY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Pharmaceuticals: Major, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
Belgium
Anderlecht